These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Fu L; Lin-Lee YC; Pham LV; Tamayo A; Yoshimura L; Ford RJ Blood; 2006 Jun; 107(11):4540-8. PubMed ID: 16497967 [TBL] [Abstract][Full Text] [Related]
6. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. Landau DA; Rosenzwajg M; Saadoun D; Klatzmann D; Cacoub P Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450 [TBL] [Abstract][Full Text] [Related]
7. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135 [TBL] [Abstract][Full Text] [Related]
9. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Shivakumar L; Ansell S Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820 [TBL] [Abstract][Full Text] [Related]
10. B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro. Stewart DM; McAvoy MJ; Hilbert DM; Nelson DL Clin Immunol; 2003 Nov; 109(2):137-43. PubMed ID: 14597212 [TBL] [Abstract][Full Text] [Related]
11. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice. Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010 [TBL] [Abstract][Full Text] [Related]
12. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597 [TBL] [Abstract][Full Text] [Related]
13. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Nimmanapalli R; Lyu MA; Du M; Keating MJ; Rosenblum MG; Gandhi V Blood; 2007 Mar; 109(6):2557-64. PubMed ID: 17119117 [TBL] [Abstract][Full Text] [Related]
14. The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas. Paterson JC; Tedoldi S; Craxton A; Jones M; Hansmann ML; Collins G; Roberton H; Natkunam Y; Pileri S; Campo E; Clark EA; Mason DY; Marafioti T Haematologica; 2006 Jun; 91(6):772-80. PubMed ID: 16769579 [TBL] [Abstract][Full Text] [Related]
16. Adhesion molecule profiles of B-cell non-Hodgkin's lymphomas in the leukemic phase. Matos DM; Rizzatti EG; Garcia AB; Gallo DA; Falcão RP Braz J Med Biol Res; 2006 Oct; 39(10):1349-55. PubMed ID: 17053842 [TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Novak AJ; Bram RJ; Kay NE; Jelinek DF Blood; 2002 Oct; 100(8):2973-9. PubMed ID: 12351410 [TBL] [Abstract][Full Text] [Related]
18. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Carbone A; Gloghini A; Gruss HJ; Pinto A Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367 [TBL] [Abstract][Full Text] [Related]